Novo Nordisk A/S (NYSE:NVO)
| 99.65 Delayed Data As of 4:01pm ET |  -0.74 / -0.74%Today’s Change | 91.51 Today|||52-Week Range 122.16 | -11.03% Year-to-Date |
Latest NVO News | Press Releases
| Top Analyst Reports for Novo Nordisk, Suncor Energy, & Nasdaq 1:05pm / Zacks.com - Paid Partner Content | SNY vs. NVO: Which Stock Should Value Investors Buy Now? Sep 20 / Zacks.com - Paid Partner Content |
| This Big Pharma Stock Just Got an Upgrade. Is It Time to Buy? Sep 27 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 100.39 |
| Today’s open | 100.20 |
| Day’s range | 99.58 - 100.72 |
| Volume | 1,068,248 |
| Average volume (3 months) | 1,565,084 |
| Market cap | $170.3B |
Data as of 4:01pm ET, 09/30/2022
Growth & Valuation
| Earnings growth (last year) | +19.70% |
| Earnings growth (this year) | +4.55% |
| Earnings growth (next 5 years) | +16.50% |
| Revenue growth (last year) | +15.27% |
| P/E ratio | 34.2 |
| Price/Sales | 11.53 |
| Price/Book | 20.63 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AZNAstraZeneca | -0.08 | -0.15% |
| NVSNovartis | -0.60 | -0.78% |
| BMYBristol-Myers Squibb | -0.59 | -0.82% |
| MRKMerck | -0.46 | -0.53% |
Data as of 4:02pm ET, 09/30/2022
Financials
| Next reporting date | November 2, 2022 |
| EPS forecast (this quarter) | $0.84 |
| Annual revenue (last year) | $22.4B |
| Annual profit (last year) | $7.6B |
| Net profit margin | 33.92% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |
Forecasts
